197 results about "Pulmonary disorders" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention discloses a method and a system for extracting a region of interest of a lung disease pathology full-slice image, relates to extraction of a region of interest, and aims to solve the technical problem of low accuracy of region of interest extraction in the prior art. Comprising the following steps: acquiring lung image data and calculating a semantic similarity score and a visual representation vector of each block; obtaining an optimal threshold according to the semantic similarity score, and screening out an index set; clustering the visual representation vectors of the blocks in the index set, and selecting the block with the highest semantic similarity score in each cluster as a representative block to obtain the index set; and based on the index set, extracting a feature matrix of each representative block, and backtracking to a space coordinate position of each representative block in the corresponding lung image data through an index to obtain a region of interest. Self-adaptive threshold filtering and recognition are carried out according to the semantic similarity score, and heterogeneity distribution of different wettability characteristics in the slice is reserved in the selected region of interest.

The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, the bacterium H. pylori in a subjects digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

The application belongs to the field of digital medicine, and particularly relates to a chronic obstructive pulmonary disease (COPD) differential system based on digital lung sound, a construction method and application thereof. The system comprises a data acquisition module, a preprocessing module, a conversion module, a data module, a data processing module, a data enhancement training module, a deep learning module, a differential module, a grading module and a display module. Digital lung sound records of candidates are collected, converted into mel spectrograms, and diagnosed by using a deep neural network. The candidates are COPD patients, healthy people, or people suffering from other lung diseases, and the disease grade of the COPD patients is given by a device carrying the differential system. The examination only needs to collect lung sounds in clinical or other places, reduces radiation damage and possible infection risk in the conventional diagnosis process, and provides a scheme for early diagnosis of COPD, and improves the diagnosis efficiency of the respiratory department, especially the COPD disease.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The present disclosure relates to the detection of acute respiratory distress syndrome in a patient. Subjects of the present disclosure are a computer system, a method and a computer program product for detection of acute respiratory distress syndrome.

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Provided is a pharmaceutical for lung regeneration, the pharmaceutical containing vascular endothelial stem cells. Also provided is a method for producing an alveolar organoid, the method comprising a step for three-dimensional co-culture of vascular endothelial stem cells and alveolar epithelial cells. This pharmaceutical for lung regeneration is useful in the treatment of lung disease accompanied by alveolar damage, such as chronic obstructive lung diseases, infectious lung diseases, and pulmonary fibrosis.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in the form of an aerosol, and wherein the aerosol is produced by nebulizing the pharmaceutical composition using a nebulizer (100), which nebulizer comprises: a) an aerosol generator (101) comprising: - a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibrating membrane (110) with a plurality of apertures, which apertures are adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with aqueous 0,9% (w / v) sodium chloride solution; b) a chamber (105) for temporarily receiving the aerosol produced by the aerosol generator (101), wherein the chamber has an internal lumen with a volume in the range of about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol provided by the nebulizer (100) to the subject, wherein the mouthpiece has an exhalation filter (30).,

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.

The application discloses a kind of X-ray film lung disease screening systems of fusing multi-level features, including lung parenchyma segmentation module, lung disease preliminary screening module, multi-level feature construction module, lung disease screening module;Lung parenchyma segmentation module is used to obtain lung parenchyma part from complete chest X-ray film segmentation;Lung disease preliminary screening module is used to construct based on feature consistency variation auto-encoding generation adversarial network and train it, and obtains preliminary screening abnormal score using trained generation adversarial network;Multi-level feature construction module is used to extract features of different semantic levels, including the extraction of bottom visual features, middle layer depth features and high layer experience features;Lung disease screening module is used to construct lung disease screening model using multi-level features and the abnormal score obtained by lung disease preliminary screening module, and obtains the final lung disease classification result.The present application can effectively solve the problem that current computer-aided lung disease screening field research is difficult to be applied to practical clinical scene.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

Embodiments provided herein include systems and methods for determining extubation readiness. One embodiment of a method includes obtaining pulse oximeter data and ventilator data for a patient that has been intubated over a predetermined monitoring period, classifying a lung disease state of the patient as acute or chronic based on at least one of the following: an age of the patient or a clinical indicator, and providing the pulse oximeter data, the ventilator data, and a lung disease classification to a trained predictive model previously trained on training data. Some embodiments include calculating a likelihood of extubation success or failure within a clinically relevant time window, and generating at least one of the following: a positive predictive value (PPV) or a negative predictive value (NPV) and generating and presenting, by the computing device, a readiness output based on the likelihood of extubation success or failure for determining extubation timing.

The application discloses application of phenyllactic acid or a composition containing phenyllactic acid in preparation of a drug for relieving lung diseases, wherein the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, the phenyllactic acid can effectively intervene in an inflammatory factor cascade reaction and an oxidative stress damage process, and significantly improve symptoms of acute lung injury caused by the above factors. Compared with a traditional treatment method, experiments prove that the phenyllactic acid or the composition containing the phenyllactic acid can significantly relieve symptoms of acute lung injury (ALI) of a mouse induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of the mouse induced by bleomycin, effectively improve pathological changes of the lung, and restore lung function.

The invention discloses an iRGD-modified mesenchymal stem cell outer vesicle-loaded WZ35 dual-targeting drug delivery composition, which is characterized in that rat bone marrow mesenchymal stem cell-derived extracellular vesicles are used as carriers, curcumin analogues WZ35 are loaded in the carriers, and iRGD peptides are covalently modified on the surfaces of the carriers, so that passive targeting and active targeting synergistic delivery is realized; efficient entrapment of the medicine is achieved in an extrusion or co-incubation mode, the particle size of the obtained composition is 100-200 nm, and the dispersity is good; in-vivo experiments show that compared with free WZ35, the composition has the advantages that the enrichment efficiency of WZ35 in lung tissue is remarkably improved, right ventricular systolic pressure can be effectively reduced in an anoxia-induced pulmonary arterial hypertension rat model, pulmonary vascular remodeling is improved, and the invention provides a novel efficient and safe drug delivery strategy for targeted therapy of lung diseases.

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses a polymorphic form and an amorphous form of ziyuglycoside II sodium salt as well as a preparation method and application of the polymorphic form and the amorphous form, and particularly discloses physicochemical properties of the polymorphic form and the amorphous form of the ziyuglycoside II sodium salt (ZYG-II-Na) and application of the ziyuglycoside II sodium salt in preparation of medicines. Compared with ziyuglycoside II, the polymorphic ZYG-II-Na and the amorphous ZYG-II-Na obtained by means of crystal form screening and solid engineering have higher solubility and dissolution rate, and the bioavailability of the ziyuglycoside II in vivo is remarkably improved. In addition, in-vitro evaluation and pharmacokinetic tests show that the ZYG-II-Na has good pharmacokinetic characteristics and treatment potential when being used for treating lung diseases (such as through an inhalation way).